Systemic corticosteroids show no benefit in severe and critical COVID-19 patients in Wuhan, China: A retrospective cohort study

Running title: Corticosteroids show no good in COVID-19

Jianfeng Wu,1,# Jianqiang Huang,2,# Guochao Zhu,3,# Yihao Liu,4,5,# Han Xiao,6,# Qian Zhou,4# Xiang Si,1 Hui Yi,2 Cuiping Wang,1 Daya Yang,7 Shuling Chen,6 Xin Liu,8 Zelong Liu,6 Qiongya Wang,9 Qingquan Lv,10 Ying Huang,11 Yang Yu,12 Xiangdong Guan,1 Yanbing Li,5 Krishnarajah Nirantharakumar,13,14 KarKeung Cheng,13 Sui Peng,4# Haipeng Xiao,5,15#

Affiliations:

1Department of Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, People’s Republic of China

2Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, People’s Republic of China

3Department of Critical Care Medicine, The Affiliated Hospital of Jianghan University (No. Six Hospital of Wuhan), Wuhan, Hubei, 430014, People’s Republic of China

4Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People’s Republic of China

5Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People’s Republic of China

6Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
510080, People’s Republic of China

7Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People’s Republic of China

8Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, People’s Republic of China

9Department of Critical Care Medicine, Wuhan Hankou Hospital, Wuhan, Hubei, 430014, People’s Republic of China

10Department of Gastrointestinal Surgery, Wuhan Hankou Hospital, Wuhan, Hubei, 430014, People’s Republic of China

11Science and Education Section, Wuhan Hankou Hospital, Wuhan, Hubei, 430014, People’s Republic of China

12Department of Gastrointestinal Surgery, The Affiliated Hospital of Jianghan University (No. Six Hospital of Wuhan), Wuhan, Hubei, 430014, People’s Republic of China

13Institute of Applied Health Research, University of Birmingham, United Kingdom

14Health Data Research UK, United Kingdom

15Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, People’s Republic of China

*These authors contributed equally to this work.

*Corresponding authors:

Haipeng Xiao, Ph.D.
Keywords: Systemic corticosteroids; mortality; severe and critical; COVID-19.
Abstract:

Background: Systemic corticosteroids are recommended by some treatment guidelines and used in severe and critical COVID-19 patients, though evidence supporting such use is limited.

Methods: From December 26, 2019 to March 15, 2020, 1514 severe and 249 critical hospitalized COVID-19 patients were collected from two medical centers in Wuhan, China. We performed multivariable Cox models, Cox model with time-varying exposure and propensity score analysis (both inverse-probability-of-treatment-weighting (IPTW) and propensity score matching (PSM)) to estimate the association of corticosteroid use with the risk of in-hospital mortality among severe and critical cases.

Results: Corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to no corticosteroid use group, systemic corticosteroid use showed no benefit in reducing in-hospital mortality in both severe cases (HR=1.77, 95% CI: 1.08-2.89, p=0.023), and critical cases (HR=2.07, 95% CI: 1.08-3.98, p=0.028). In the time-varying Cox analysis that with time varying exposure, systemic corticosteroid use still showed no benefit in either population (for severe patients, HR=2.83, 95% CI: 1.72-4.64, p<0.001; for critical patients, HR=3.02, 95% CI: 1.59-5.73, p=0.001). Baseline characteristics were matched after IPTW and PSM analysis. For severe COVID-19 patients at admission, corticosteroid use was not associated with improved outcome in either the IPTW analysis. For critical COVID-19 patients at admission, results were consistent with former analysis that corticosteroid use did not reduce in-hospital mortality.

Conclusions: Corticosteroid use showed no benefit in reducing in-hospital mortality for severe or critical cases. The routine use of systemic corticosteroids among severe and critical COVID-19 patients was not recommended.
Introduction

The current pandemic of coronavirus disease-19 (COVID-19) has become the most severe global health crisis [1]. At present, the cumulative number of confirmed COVID-19 cases worldwide has exceeded 3 million and is still rising rapidly [2]. Although most of COVID-19 patients reportedly had mild symptoms and good prognosis, the mortality of hospitalized severe and critical cases was 18.2% and 49%, respectively [3,4]. Due to the lack of specific therapies for COVID-19, one of the biggest challenges faced by clinicians in all countries is the clinical management of severe and critical cases with the goal of reducing mortality.

Systemic corticosteroids have been studied extensively with variable and inconsistent results in the treatment of acute respiratory distress syndrome (ARDS) caused by viral pneumonia [5-7]. During the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), systemic corticosteroids were used in 79.6% and 48.9% of critical cases, respectively [5,8]. Two studies of patients with SARS and influenza A (H1N1) viral pneumonia showed that the use of systemic corticosteroids was associated with reduced mortality in critical patients [6,8]. However, several other studies of patients with SARS and one study of patients with MERS all indicated that its use could be harmful [5,9-12]. A meta-analysis published in 2019 also showed a significant increase in mortality in influenza pneumonia patients treated with systemic corticosteroids [13]. The COVID-19 treatment guidelines released by the China’s National Health Commission recommended low-dose and short-term use of systemic corticosteroids for patients with rapidly worsening conditions [14-16]. Systemic corticosteroids were used in 44.5% of severe COVID-19 patients in China [17]. However, its routine use is not recommended by the World Health Organization (WHO) clinical management guidelines for patients with severe acute respiratory infection when COVID-19 is suspected [18]. In view of the small sample size and the lack of matched controls in all previous studies, large scale studies are urgently needed to provide evidence of
harm or benefit for the use of systemic corticosteroids in severe and critical COVID-19 patients.

In the current study, we analysed the clinical data of 1514 severe and 249 critical COVID-19 cases from two medical centres in Wuhan city and investigated the effects of systemic corticosteroids in severe and critical COVID-19 patients.

Methods

Study Population

Consecutive inpatients with laboratory confirmed or clinically diagnosed COVID-19 from Wuhan Hankou Hospital and No. Six Hospital of Wuhan between December 26th, 2019 and March 15th, 2020 were collected in this study. The final follow up date was March 19th, 2020. Patients who met any of the following conditions were exclude from the study: 1. Non severe or critical cases; 2. Not being diagnosed as severe cases within 24 hours since admission; 3. The time of being diagnosed of severe/critical cases were missing. Severe cases were defined as those who required oxygen therapy during hospital stay. Critical cases were those who met any of the following conditions during the whole hospital stay: 1. mechanical ventilation was required; 2. required treatment in intensive care unit (ICU); 3. shock occurred in hospital [16].

This study was approved by the ethics committees of Wuhan Hankou Hospital, No. Six Hospital of Wuhan and the First Affiliated Hospital of Sun Yat-sen University, and the informed consent was waived. The study followed the tenets of the Declaration of Helsinki and is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline.

Data Collection and Definition

We collected the patients’ clinical data, including demographic information, medical history, laboratory indexes, corticosteroid use and prognosis. The admission
laboratory indexes were defined as the first records of laboratory indexes since admission. Corticosteroid use was defined as the use of intravenous systemic corticosteroids, including hydrocortisone, methylprednisolone, and dexamethasone. The dose of corticosteroids was converted to methylprednisolone-equivalent doses (1mg methylprednisolone = 0.1875mg dexamethasone = 5mg hydrocortisone).

**Exposure and Outcome**

We evaluated whether using corticosteroids could affect the in-hospital mortality of severe/critical cases. The time to death was defined as the time of being diagnosed of severe/critical cases to the date of death from any cause in hospital.

**Statistical Analysis**

Data were expressed as mean and standard deviation (SD) if normally distributed, and median and interquartile range (IQR) with non-normal distribution, and frequency and percentages for categorical variables. We compared baseline characteristics and outcomes of patients who received corticosteroids and those who did not receive any corticosteroid using Students’ t test, Mann-Whitney test for continuous variables, and chi-square test or Fisher exact test for categorical variables. Survival with or without corticosteroid use was analysed using the Kaplan-Meier method and compared by log-rank test. The 28-day in-hospital mortality and its 95% confidence interval was reported for both corticosteroid use and non-corticosteroid use groups. We evaluated the associations between corticosteroid use and prognosis using two approaches. First, multivariable Cox regression models were applied to evaluate the association between corticosteroid use and mortality. Multivariable analysis was adjusted for age, gender, admission laboratory indexes (including lymphocyte, neutrophil granulocyte, platelet, haemoglobin, glucose, C-reaction protein (CRP), lactate dehydrogenase (LDH), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), pulse oxygen saturation (SpO2), hypertension, diabetes, cancer, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD) and
smoking history. The proportion of missing values of baseline variables was 4.5%, ranging from 0% to 10.6%. The missing data were imputed by multiple imputation for ten times in the multivariable analysis. Second, in Cox regression models, corticosteroid use was accounted as a time-varying exposure to mitigate immortal time bias. In time-varying analysis, data was reconstructed according to the time of corticosteroid use. Therefore, time from a diagnosis of severe/critical case to time of corticosteroid use was categorized as unexposed. The hazards ratios (HRs) and 95% confidence intervals (CIs) of Cox regression models were reported.

We also performed propensity score driven analysis (inverse-probability-of-treatment-weighting (IPTW) and propensity score matching (PSM)) to account for confounding by indication bias in the above mentioned two approaches [19,20]. Multivariable logistic regression was carried out with corticosteroid use as a binary outcome to obtain the predicted probability of corticosteroid use, which was taken as propensity score (PS). All baseline characteristics were used to construct PS for each three parts of patients. In IPTW, for the group with corticosteroids therapy, the weight was equal to 1/PS, while for the group without corticosteroids therapy, the weight was equal to 1/(1-PS). In PSM, calliper value was set as 20% of the standard deviation of propensity scores. We reported the results of multivariable Cox regression, also Cox regression with time-varying exposure before matching and after matching (IPTW and PSM) for all association analysis. Wilcoxon signed-rank test was used for pairwise comparison of mean blood glucose and lymphocytes before, during and after the use of corticosteroids, and method of Bonferroni was used for correction. The distribution of the length of corticosteroid use was plotted by bar chart for both severe and critical patients. We used Stata/MP 14.0 to conduct all data analyses, and statistical significance was set as p<0.05 bilaterally.
Results

Baseline characteristics

From Dec 26th, 2019 to Mar 15th, 2020, a total of 2289 consecutive cases of COVID-19 hospitalized patients were collected from two medical centres in Wuhan, China. After excluding non-severe/critical cases (n=126), cases without the exact severe or critical diagnosis timepoint (n=202) and severe or critical cases not being diagnosed on the day of admission (n=198), a total of 1763 COVID-19 hospitalized severe or critical cases were included. Among them, 85.9% (1514/1763) patients were severe cases at admission, and 14.1% (249/1763) patients were critical cases at admission.

Table 1 showed the baseline characteristics of 1514 severe cases at admission. The median age was 61.0 years (IQR: 51.0, 70.0), and 790 (52.2%) were female. The median in-hospital stay was 12.7 days (IQR: 7.5, 19.8). Among them, 531 (35.1%) patients received systemic corticosteroids with a daily average dose equivalent to 40.0 mg (IQR: 37.3, 57.1) methylprednisolone, and 67.6% (359/531) started corticosteroid use within 24 hours after being diagnosed as severe cases. The median initial time of corticosteroid use since being diagnosed as severe cases was 2.2 (0.1, 41.5) hours, and the duration of corticosteroid use lasted 6.0 (3.0, 10.0) days. When comparing the baseline characteristics between corticosteroid use group and non-corticosteroid use group, there were significant differences in age, gender, several admission laboratory values and smoking (p<0.05).

Table 2 showed the baseline characteristics of 249 critical cases at admission. The median age was 68.0 years (IQR: 58.0, 78.0), and 102 (41.0%) were female. The median in-hospital stay was 13.9 days (IQR: 5.8, 22.6). Among them, 159 (63.9%) patients received systemic corticosteroids with a daily average dose equivalent to 40.0 mg (IQR: 40.0, 60.0) methylprednisolone, and 79.9% (127/249) started corticosteroid use within 24 hours after being diagnosed as critical cases. The median initial time of
corticosteroid use since being diagnosed as critical cases was 0.1 (0, 16.1) hours, and the duration of corticosteroid use lasted 5.0 (3.0, 7.0) days. When comparing the baseline characteristics between corticosteroid use group and non-corticosteroid use group, there were significant differences in several admission laboratory values (p<0.05).

**Systemic corticosteroid use showed no benefit in reducing in-hospital mortality in severe cases**

For all 1514 severe cases, we analysed the factors associated with in-hospital mortality. Kaplan-Meier survival curve showed that in-hospital mortality was significantly higher in the corticosteroid use group than in the no corticosteroid use group (log-rank test p<0.001). The 28-day in-hospital mortality was 20.6% (95% CI: 16.5%-25.6%) in the corticosteroid use group while 3.7% (95% CI: 2.3%-6.0%) for no corticosteroid use. The results of univariate regression model were shown in Supplementary Table 1. In the multivariable Cox model, systemic corticosteroid use was independently associated with in-hospital mortality (HR=1.77, 95% CI: 1.08-2.89, p=0.023) (Table 3). In the multivariable Cox model with time-varying exposure, systemic corticosteroid use was independently associated with in-hospital mortality (HR=2.83, 95% CI: 1.72-4.64, p<0.001). After IPTW and PSM (baseline shown in Supplementary Tables 2 and 3), the results showed tendency towards the association between systemic corticosteroid use and increased in-hospital mortality after both propensity score analysis (HR=1.43, 95% CI: 0.82-2.49, p=0.201 in IPTW; HR=1.55, 95% CI: 0.83-2.87, p=0.166 in PSM). Kaplan-Meier survival curves after IPTW and PSM were shown in Figure 1A and 1B.

**Systemic corticosteroid use showed no benefit in reducing in-hospital mortality in critical cases**

For all 249 critical cases, we analysed the factors associated with in-hospital mortality. Compared with the no corticosteroid use group, the in-hospital mortality was
significantly higher in the corticosteroid use group (log-rank test p<0.001). The 28-day in-hospital mortality was 51.0% (95% CI: 42.2%-60.5%) in the corticosteroid use group and 17.0% (95% CI: 10.0%-28.1%) in the no corticosteroid use group, respectively. The results of univariate regression model were shown in Supplementary Table 4. In the multivariable Cox model, systemic corticosteroid use was independently associated with increased in-hospital mortality (HR=2.07, 95% CI: 1.08-3.98, p=0.028) (Table 4). In the multivariable Cox model with time-varying exposure, systemic corticosteroid use was also independently associated with increased in-hospital mortality (HR=3.02, 95% CI: 1.59-5.73, p=0.001). After IPTW and PSM (baseline shown in Supplementary Tables 5 and 6), the results supported that systemic corticosteroid use was independently associated with increased in-hospital mortality in critical cases after both propensity score analysis (HR=3.34, 95% CI: 1.84-6.05, p<0.001 in IPTW; HR=2.90, 95% CI: 1.17-7.16, p=0.021 in PSM). Kaplan-Meier survival curves after IPTW and PSM were shown in Figure 1C and 1D.

**Discussion**

In the present study, we investigated the effect of systemic corticosteroids on clinical outcomes in 1514 severe and 249 critical COVID-19 cases from Wuhan. Corticosteroids were used in 35.1% and 63.9% in severe and critical cases, respectively. The use of corticosteroids was mainly low-dose and short-term. Corticosteroid use showed no benefit in reducing in-hospital mortality either in severe or in critical COVID-19 cases. The above results were consistent across multivariable Cox regression and Cox model with time-varying exposure; and after propensity score driven analysis (both IPTW and PSM).

Acute respiratory failure was one of the leading causes of death for severe COVID-19 patients. Since there is no specific treatment for coronavirus infection, the current treatment mainly relies on supportive care and oxygen therapy, drawing
largely on previous experience in treating SARS and MERS. The use of systemic corticosteroids is one of the most controversial interventions [21]. Two studies on SARS and H1N1 viral pneumonia indicated that use of corticosteroids could reduce mortality in critical patients [6,8]. An observational study by Zhou et al. with 15 COVID-19 patients demonstrated that an improvement in oxygen saturation and arterial partial pressure of oxygen (PaO2)/oxygen fraction (FiO2) was observed 3-5 days after the use of systemic corticosteroids [22], therefore advocating for the use of systemic corticosteroids in patients with severe COVID-19 for a short term. The latest COVID-19 treatment guidelines of the China’s National Health Commission recommended systemic corticosteroid use in severe COVID-19 patients under certain circumstances. However, strong evidence supporting their recommendations is absent. This large observational study found that the use of systemic corticosteroids was not associated with improved outcomes for severe and critical COVID-19 patients.

The rationale for corticosteroid use includes its potential role in suppressing inflammatory storm, reducing inflammatory exudation, and preventing multiple organs injuries in acute respiratory failure. However, its multifaceted negative impacts on prognosis should not be overlooked. Previous studies suggested that the viral load of the novel coronavirus significantly aggravated the severity of the COVID-19 [23]. Systemic corticosteroids may have worsened prognosis by promoting virus replication. Immunity may also be suppressed by the use of systemic corticosteroids [24]. Our results showed that median lymphocyte count remained low during the use of systemic corticosteroids, which might lead to a higher risk of superinfections. Systemic corticosteroids could also induce hyperglycaemia, which was shown to be an independent risk factor for the prognosis of infection and critically ill patients [25-27]. We also found that median blood glucose level was higher during the use of systemic corticosteroids (The change of lymphocyte count and blood glucose level before, during and after corticosteroid use were shown in Supplementary Table 7). In addition, systemic corticosteroids were more likely to cause complications in the
elderly – the median age of severe and critical COVID-19 patients being 61.0 and 68.0 years, respectively in this cohort [28,29].

In this study, the baseline characteristics between the corticosteroid use group and the non-corticosteroid use group were unbalanced. In order to reduce the risk of confounding by indication bias, we performed two different methods of propensity score analysis, namely IPTW and PSM. Baseline characteristics were well balanced after matching, but corticosteroid use was not associated with reduced risk of in-hospital mortality. Since patients in the corticosteroid group were unexposed before the initiation of treatment, the use of corticosteroids was also taken as a time-dependent variable to reduce immortality time bias. The results of time-dependent analysis still showed no benefit of the systemic corticosteroids, indicating that our results are robust. Particularly, after matching and using time-dependent analysis, we could observe that the K-M survival curves of corticosteroid use and no corticosteroid use group were close to each other during the first 7 days in both severe and critical cases. The cumulative mortality in first 7 days was similar in two groups, which indicated that the difference in overall mortality was more likely to be caused by the use of systemic corticosteroids, rather than the difference in baseline characteristics.

The major limitation of this study is retrospective nature. Although it was a large scale and the baseline characteristics were balanced between two groups after performing propensity score analysis and time-dependent analysis, our finds should be further validated in randomised controlled trial.

In summary, this large observational study shows that there is no evidence of clinical benefit for the use of corticosteroids in severe and critical COVID-19 patients. We do not recommend its routine use outside a trial setting.
Acknowledgements: We thank all the hospital staff members for their efforts in working in the front line.

Financial support: None.

Data Availability Statements: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Potential conflict of interests: All authors declared there were no conflicts of interest.
Supplementary material

Supplementary Table 1. Association of variables and in-hospital mortality in severe COVID-19 patients in univariable Cox regression analysis.

Supplementary Table 2. Baseline comparison between corticosteroid use and no corticosteroid use groups after inverse probability of treatment weighted in severe COVID-19 patients.

Supplementary Table 3. Baseline comparison between corticosteroid use and no corticosteroid use groups after propensity score matching in severe COVID-19 patients.

Supplementary Table 4. Association of variables and in-hospital mortality in critical COVID-19 patients in univariable Cox regression analysis.

Supplementary Table 5. Baseline comparison between corticosteroid use and no corticosteroid use groups after inverse probability of treatment weighted in critical COVID-19 patients.

Supplementary Table 6. Baseline comparison between corticosteroid use and no corticosteroid use groups after propensity score matching in critical COVID-19 patients.

Supplementary Table 7. Blood glucose level and lymphocyte counts in severe and critical COVID-19 patients with or without corticosteroid use.
References:

1. World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.who.int. Accessed 2 May 2020.
2. World Health Organization. Coronavirus disease (COVID-19) situation reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 2 May 2020.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
4. Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. [An update on the epidemiological characteristics of novel coronavirus pneumoniaCOVID-19]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:139-144.
5. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197:757-767.
6. Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses. 2017;11:345-354.
7. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.
8. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucocorticoids: the Guangzhou experience. Chest. 2006;129:1441-1452.
9. Lee DT, Wing YK, Leung HC, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis. 2004;39:1247-1249.
10. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304-309.
11. Li YM, Wang SX, Gao HS, et al. [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. Zhonghua Yi Xue Za Zhi. 2004;84:1348-1353.
12. Xiao JZ, Ma L, Gao J, et al. [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]. Zhonghua Nei Ke Za Zhi. 2004;43:179-182.
13. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99.
14. National Health Commission of the People’s Republic of China. The 5th trial version of Diagnosis and Treatment Scheme for Pneumonitis caused by COVID-19 Infection (In Chinese). Available at: http://www.nhc.gov.cn/yzwj/s7653p/202002/d4b895337e194458d728fca1e3e13a.shtml. Accessed 2 May 2020.
15. National Health Commission of the People’s Republic of China. The 6th trial version of Diagnosis and Treatment Scheme for Pneumonitis caused by COVID-19 Infection (In Chinese). Available at: http://www.nhc.gov.cn/yzwj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. Accessed 2 May 2020.
16. National Health Commission of the People’s Republic of China. The 7th trial version of Diagnosis and Treatment Scheme for Pneumonitis caused by COVID-19 Infection (In Chinese). Available at:
http://www.nhc.gov.cn/zyyjg/z7653p/202003/46c9294a7defe4c9f80de7f5912eb1989.shtml. Accessed 2 May 2020.

17. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [in press].

18. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 2 May 2020.

19. Ali MS, Groenwold RH, Belitser SV, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. J Clin Epidemiol. 2015;68:112-121.

20. Mansournia MA, Altman DG. Inverse probability weighting. BMJ. 2016;352:i189.

21. Russel CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-475.

22. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18.

23. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364-374.

24. Brass D, McKay P, Scott F. Investigating an incidental finding of lymphopenia. BMJ. 2014;348:g1721.

25. Roberts GW, Quinn SJ, Valentine N, et al. Relative Hyperglycemia, a Marker of Critical Illness: Introducing the Stress Hyperglycemia Ratio. J Clin Endocrinol Metab. 2015;100:4490-4497.

26. Lee TF, Drake SM, Roberts GW, et al. Relative Hyperglycemia Is an Independent Determinant of In-Hospital Mortality in Patients With Critical Illness. Crit Care Med. 2020;48:e115-e122.

27. Park BS, Yoon JS, Moon JS, Won KC, Lee HW. Predicting mortality of critically ill patients by blood glucose levels. Diabetes Metab J. 2013;37:385-390.

28. Mascllee GMC, Valkhoff VE, Coloma PM, et al. Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations. Gastroenterology. 2014;147:784-792.

29. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
| Characteristic                      | Total (n=1514) | No Corticosteroid (n=983) | Corticosteroid (n=531) | P value |
|------------------------------------|----------------|--------------------------|------------------------|---------|
| **Age, y**                         | 61.0 (51.0, 70.0) | 60.0 (50.0, 69.0)         | 63.0 (53.0, 71.0)      | 0.001   |
| **Female, n (%)**                  | 790 (52.2)      | 550 (56.0)                | 240 (45.2)             | <0.001  |
| **Comorbid conditions, n (%)**     |                |                          |                        |         |
| Diabetes                           | 181 (12.0)      | 110 (11.2)                | 71 (13.4)              | 0.214   |
| Hypertension                       | 354 (23.4)      | 232 (23.6)                | 122 (23.0)             | 0.799   |
| COPD                               | 42 (2.8)        | 26 (2.6)                  | 16 (3.0)               | 0.743   |
| Cancer                             | 22 (1.5)        | 17 (1.7)                  | 5 (0.9)                | 0.266   |
| CKD                                | 29 (1.9)        | 21 (2.1)                  | 8 (1.5)                | 0.439   |
| Smoking                            | 185 (12.2)      | 107 (10.9)                | 78 (14.7)              | 0.033   |
| **Admission laboratory values**    |                |                          |                        |         |
| Admission glucose, mmol/L          | 6.0 (5.2, 7.5)  | 5.8 (5.0, 6.8)            | 6.8 (5.7, 8.4)         | <0.001  |
| Lymphocyte counts, 10^9/L          | 1.0 (0.7, 1.4)  | 1.2 (0.8, 1.5)            | 0.7 (0.5, 1.0)         | <0.001  |
| Neutrophil counts, 10^9/L          | 3.7 (2.6, 5.2)  | 3.6 (2.6, 4.7)            | 4.1 (2.7, 6.5)         | <0.001  |
| Platelet counts, 10^9/L            | 199.0 (151.0, 251.8) | 211.0 (163.0, 257.0) | 176.0 (138.0, 233.0) | <0.001  |
| Haemoglobin, g/L                   | 127.0 (116.0, 137.0) | 126.0 (115.0, 136.0) | 129.0 (118.0, 139.0) | 0.001   |
| CRP, mg/L                          | 24.8 (4.8, 47.8) | 13.8 (2.0, 42.3)          | 35.7 (20.9, 64.7)      | <0.001  |
| SpO₂, %                            | 97.0 (95.0, 99.0) | 98.0 (96.0, 99.0)         | 96.0 (92.0, 98.0)      | <0.001  |
| Lactate, mmol/L                    | 1.6 (1.3, 2.1)  | 1.6 (1.3, 2.1)            | 1.6 (1.3, 2.2)         | 0.471   |
| LDH, U/L                           | 224.6 (179.0, 310.0) | 202.1 (166.0, 266.1) | 285.0 (212.6, 375.6) | <0.001  |
| AST, U/L                           | 26.0 (18.2, 38.2) | 23.0 (16.9, 34.0)         | 31.0 (23.8, 46.0)      | <0.001  |
| ALT, U/L                           | 24.2 (15.9, 37.0) | 23.0 (15.0, 36.0)         | 26.0 (18.0, 39.6)      | <0.001  |
| D-Dimer, mg/L                      | 0.4 (0.2, 0.8)  | 0.4 (0.2, 0.7)            | 0.5 (0.2, 1.1)         | <0.001  |
## Medications

The initial time of corticosteroid use since being diagnosed as severe cases, h

| Time          | No Corticosteroid (n=983) | Corticosteroid (n=531) | P value |
|---------------|---------------------------|------------------------|---------|
| ≤24 hours     | -                         | -                      | -       |
| 24-48 hours   | -                         | -                      | -       |
| 48-72 hours   | -                         | -                      | -       |
| >72 hours     | -                         | -                      | -       |

Accumulative corticosteroid dose, mg*

| Duration of corticosteroid use, d | No Corticosteroid (n=983) | Corticosteroid (n=531) | P value |
|----------------------------------|---------------------------|------------------------|---------|
| -                                | 6.0 (3.0, 10.0)           | 6.0 (3.0, 10.0)        | -       |

Daily average corticosteroid dose, mg

| Daily average corticosteroid dose, mg | No Corticosteroid (n=983) | Corticosteroid (n=531) | P value |
|--------------------------------------|---------------------------|------------------------|---------|
| -                                    | 40.0 (37.3, 57.1)         | 40.0 (37.3, 57.1)      | -       |

### Disease severity

| Characteristic                  | No Corticosteroid (n=983) | Corticosteroid (n=531) | P value |
|---------------------------------|---------------------------|------------------------|---------|
| In-hospital stay, d             | 11.5 (6.9, 17.8)          | 15.2 (9.1, 23.8)       | <0.001  |
| Progression to critical cases, n (%) | 104 (10.6)              | 149 (28.1)             | <0.001  |
| Death, n (%)                    | 26 (2.6)                  | 83 (15.6)              | <0.001  |

* The dose of corticosteroids was converted to methylprednisolone-equivalent doses.

Abbreviations: COVID-19, coronavirus disease 2019; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CRP, C-reactive protein; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen.
Table 2. Demographics and baseline characteristics of 249 critical COVID-19 patients at admission.

| Characteristic               | Total (n=249) | No Corticosteroid (n=90) | Corticosteroid (n=159) | P value |
|------------------------------|---------------|--------------------------|------------------------|---------|
| Age, y                       | 68.0 (58.0, 78.0) | 67.0 (54.0, 82.0)        | 68.0 (60.0, 75.0)      | 0.340   |
| Female, n (%)                | 102 (41.0)    | 37 (41.1)                | 65 (40.9)              | >0.999  |
| Comorbid conditions, n (%)   |               |                          |                        |         |
| Diabetes                     | 56 (22.5)     | 21 (23.3)                | 35 (22.0)              | 0.875   |
| Hypertension                 | 107 (43.0)    | 39 (43.3)                | 68 (42.8)              | >0.999  |
| COPD                         | 24 (9.6)      | 12 (13.3)                | 12 (7.5)               | 0.179   |
| Cancer                       | 6 (2.4)       | 1 (1.1)                  | 5 (3.1)                | 0.423   |
| CKD                          | 15 (6.0)      | 9 (10.0)                 | 6 (3.8)                | 0.056   |
| Smoking                      | 56 (22.5)     | 18 (20.0)                | 38 (23.9)              | 0.530   |
| Admission laboratory values  |               |                          |                        |         |
| Admission glucose, mmol/L    | 6.9 (5.7, 8.5) | 6.1 (5.2, 7.7)           | 7.3 (6.2, 8.7)         | <0.001  |
| Lymphocyte counts, 10^9/L    | 0.7 (0.5, 1.1) | 0.9 (0.6, 1.3)           | 0.6 (0.4, 1.0)         | <0.001  |
| Neutrophil counts, 10^9/L    | 4.9 (3.5, 8.2) | 4.0 (3.0, 5.8)           | 5.9 (3.8, 9.5)         | <0.001  |
| Platelet counts, 10^9/L      | 187.0 (141.0, 236.0) | 198.0 (149.0, 246.0) | 182.0 (137.0, 235.0) | 0.215   |
| Haemoglobin, g/L             | 126.0 (114.0, 137.0) | 123.7 (109.0, 135.0)  | 126.0 (115.3, 138.0)  | 0.054   |
| CRP, mg/L                    | 69.4 (25.7, 140.4) | 47.4 (12.0, 109.0)      | 88.1 (34.6, 151.5)     | <0.001  |
| SpO2, %                      | 95.0 (90.0, 98.0) | 97.7 (94.9, 99.0)       | 94.0 (86.0, 97.2)      | <0.001  |
| Lactate, mmol/L              | 1.6 (1.3, 2.3)  | 1.5 (1.2, 2.0)           | 1.7 (1.3, 2.4)         | 0.062   |
| LDH, U/L                     | 331.0 (208.0, 533.2) | 222.8 (162.5, 344.2) | 408.0 (265.0, 596.7) | <0.001  |
| AST, U/L                     | 33.8 (21.0, 53.0)   | 27.1 (19.3, 42.6)       | 37.5 (22.3, 57.5)      | 0.001   |
| ALT, U/L                     | 25.7 (16.6, 41.8)   | 21.2 (15.5, 35.0)       | 27.2 (17.6, 44.0)      | 0.045   |
| D-Dimer, mg/L                | 0.7 (0.4, 2.1)     | 0.5 (0.4, 1.0)          | 0.8 (0.4, 3.1)         | 0.008   |
| Characteristic | Total (n=249) | No Corticosteroid (n=90) | Corticosteroid (n=159) | P value |
|---------------|--------------|--------------------------|------------------------|---------|
| Creatinine, μmol/L | 75.7 (61.0, 104.0) | 75.6 (58.3, 101.8) | 75.8 (61.2, 104.0) | 0.878 |
| BUN, mmol/L | 5.6 (4.2, 8.5) | 5.4 (3.9, 7.8) | 5.6 (4.4, 9.2) | 0.177 |
| Medications | | | | |
| The initial time of corticosteroid use since being diagnosed as critical cases, h | | | | |
| ≤24 hours | - | - | 0.1 (0.0, 16.1) | - |
| 24-48 hours | - | - | 127 (79.9) | - |
| 48-72 hours | - | - | 6 (3.8) | - |
| >72 hours | - | - | 19 (11.9) | - |
| Accumulative corticosteroid dose, mg* | - | - | 240.0 (120.0, 360.0) | - |
| Duration of corticosteroid use, d | - | - | 5.0 (3.0, 7.0) | - |
| Daily average corticosteroid dose, mg | - | - | 40.0 (40.0, 60.0) | - |
| Disease severity | | | | |
| In-hospital stay, d | 13.9 (5.8, 22.6) | 15.6 (7.9, 24.5) | 12.9 (5.1, 21.9) | 0.203 |
| Death, n (%) | 84 (33.7) | 14 (15.6) | 70 (44.0) | <0.001 |

*The dose of corticosteroids was converted to methylprednisolone-equivalent doses.

Abbreviations: COVID-19, coronavirus disease 2019; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CRP, C-reactive protein; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen.
Table 3. Association of systemic corticosteroid use and in-hospital mortality in severe COVID-19 patients in multivariable Cox regression analysis.

| Variables                  | Before matching | Inverse probability of treatment weighted | Propensity score matching |
|----------------------------|-----------------|-------------------------------------------|---------------------------|
|                            | Cox             | Time-varying Cox                          | Time-varying Cox          |
|                            | Adjusted HR     | Adjusted HR                               | Adjusted HR               | Adjusted HR               |
|                            | (95% CI)        | (95% CI)                                  | (95% CI)                  | (95% CI)                  |
|                            | P value         | P value                                   | P value                   | P value                   |
| Systemic corticosteroid use|                 |                                           |                           |                           |
| No                         | 1.00 (reference)| 1.00 (reference)                          | 1.00 (reference)          | 1.00 (reference)          |
|                            | 1.00            | <0.001                                    | 1.43                      | 0.201                     |
| Yes                        | 1.77 (1.08, 2.89)| 2.83 (1.72, 4.64)                      | 1.55 (0.83, 2.87)         | 0.166                     |

Abbreviations: COVID-19, coronavirus disease 2019; HR, hazard ratio; CI, confidence interval.
Table 4. Association of systemic corticosteroid use and in-hospital mortality in critical COVID-19 patients in multivariable Cox regression analysis.

| Variables                  | Before matching | Inverse probability of treatment weighted | Propensity score matching |
|----------------------------|-----------------|------------------------------------------|--------------------------|
|                            | Cox             | Time-varying Cox                         | Time-varying Cox         | Time-varying Cox         |
|                            | Adjusted HR (95% CI) | Adjusted HR (95% CI) | Adjusted HR (95% CI) | Adjusted HR (95% CI) |
|                            | P value         | P value                                  | P value                  | P value                  |
| Systemic corticosteroid use| No              | 1.00 (reference)                         | 1.00 (reference)         | 1.00 (reference)         | 1.00 (reference)         |
|                            | Yes             | 2.07 (1.08, 3.98)                        | 0.028                    | 3.02 (1.59, 5.73)        | <0.001                  |
|                            |                 |                                         |                          | 3.34 (1.84, 6.05)        | <0.001                  |
|                            |                 |                                         |                          | 2.90 (1.17, 7.16)        | 0.021                   |

Abbreviations: COVID-19, coronavirus disease 2019; HR, hazard ratio; CI, confidence interval.
Figure 1. Kaplan-Meier survival curves of the corticosteroid use group and no corticosteroid use group for IPTW and PSM in-hospital mortality in severe cases (A,B), and in critical cases (C,D), respectively.

Abbreviations: IPTW, inverse-probability-of-treatment-weighting; PSM, propensity score matching.